<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03455270</url>
  </required_header>
  <id_info>
    <org_study_id>G1T48-01</org_study_id>
    <secondary_id>2017-004502-17</secondary_id>
    <nct_id>NCT03455270</nct_id>
  </id_info>
  <brief_title>G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer</brief_title>
  <official_title>A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination With Palbociclib in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G1 Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>G1 Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to investigate the potential clinical benefit of G1T48 as an oral selective
      estrogen receptor degrader (SERD) alone and in combination with palbociclib, a cyclin
      dependent kinase 4/6 (CDK 4/6) inhibitor, in patients with estrogen receptor-positive,
      HER2-negative metastatic breast cancer.

      The study is an open-label design, consisting of 3 parts: dose-finding portion including food
      effect (Part 1), G1T48 monotherapy expansion portion (Part 2), and G1T48 in combination with
      palbociclib expansion portion (Part 3). All parts include 3 study phases: Screening Phase,
      Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of first
      dose with study treatment and completes at the Post-Treatment Visit. Approximately, 184
      patients may be enrolled in the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2018</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>Cycle 1 Day -3 to Cycle 1 Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 dose</measure>
    <time_frame>12 months</time_frame>
    <description>G1T48 alone and in combination with palbociclib; progression-free survival (PFS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Treatment Related Adverse Event, including Abnormal Laboratory Events</measure>
    <time_frame>21 months</time_frame>
    <description>All AEs, including clinical laboratory, vitals signs, physical examinations and ECGs will be analyzed in all patients receiving study drug(s) from the signing of the informed consent until 30 days after the last dose of study medication(s).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response based on RECIST, Version 1.1</measure>
    <time_frame>21 months</time_frame>
    <description>G1T48 alone and in combination with palbociclib;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of food on bioavailability of G1T48</measure>
    <time_frame>Part 1, Cycle 1 Day -10 to Cycle 1 Day 1.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of G1T48 and metabolites: Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Part 1, Cycle 1 Day -3 to Cycle 2 Day 1. Part 2, Cycle 2 Day 1 to Cycle 3 Day 1. Part 3, Cycle 2 Day 1 to Cycle 3 Day 1.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of G1T48 and metabolites: Area under Curve - plasma concentration (AUC)</measure>
    <time_frame>Part 1, Cycle 1 Day -3 to Cycle 2 Day 1. Part 2, Cycle 2 Day 1 to Cycle 3 Day 1. Part 3, Cycle 2 Day 1 to Cycle 3 Day 1.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of G1T48 and metabolites: Plasma: terminal half life (T1/2)</measure>
    <time_frame>Part 1, Cycle 1 Day -3 to Cycle 2 Day 1. Part 2, Cycle 2 Day 1 to Cycle 3 Day 1. Part 3, Cycle 2 Day 1 to Cycle 3 Day 1.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of G1T48 and metabolites: Plasma - Volume of distribution</measure>
    <time_frame>Part 1, Cycle 1 Day -3 to Cycle 2 Day 1. Part 2, Cycle 2 Day 1 to Cycle 3 Day 1. Part 3, Cycle 2 Day 1 to Cycle 3 Day 1.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of palbociclib: Plasma - Trough concentration</measure>
    <time_frame>Part 3, Cycle 2 Day 1 to Cycle 3 Day 1.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Carcinoma, Ductal, Breast</condition>
  <condition>Breast Cancer Female</condition>
  <condition>Breast Neoplasm</condition>
  <condition>Breast Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Advanced Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1: Dose Escalation (G1T48)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in Part 1 will receive a single oral dose of G1T48 on Cycle 1 Day -3 and will begin once-daily dosing on Cycle 1 Day 1.
The initial dose cohort shall receive an identified starting dose and subsequent cohorts shall receive higher doses based on the safety and PK data obtained from the previous dose levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Food Effect Cohort (G1T48)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1, additional G1T48 cohort(s) of 8 patients may be enrolled to assess the effect of different fat content meals (eg, high fat, moderate fat, or low-fat) on the rate and extent of the absorption of G1T48.
Patients will receive a single oral dose of G1T48 on Cycle 1 Day -10 and on Cycle 1 Day -3. Patients will begin G1T48 once-daily dosing on Cycle 1 Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Monotherapy Dose Expansion (G1T48)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in Part 2 will receive G1T48 once-daily at the dose determined in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Combination Dose Expansion (G1T48+palbociclib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in Part 3 will receive G1T48 once-daily at the dose determined in Part 2 in combination with palbociclib once-daily on Days 1 to 21 of each 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G1T48</intervention_name>
    <description>oral SERD</description>
    <arm_group_label>Part 1: Dose Escalation (G1T48)</arm_group_label>
    <arm_group_label>Part 1: Food Effect Cohort (G1T48)</arm_group_label>
    <arm_group_label>Part 2: Monotherapy Dose Expansion (G1T48)</arm_group_label>
    <arm_group_label>Part 3: Combination Dose Expansion (G1T48+palbociclib)</arm_group_label>
    <other_name>Rintodestrant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>CDK 4/6 Inhibitor</description>
    <arm_group_label>Part 3: Combination Dose Expansion (G1T48+palbociclib)</arm_group_label>
    <other_name>Ibrance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For Part 1, postmenopausal women only

          -  For Parts 2 and 3, any menopausal status

          -  Confirmed diagnosis of ER-positive, HER2-negative advanced breast cancer, not amenable
             to curative therapy

          -  For Part 1, prior treatment with less than 4 prior lines of chemotherapy

          -  For Part 2, prior treatment with less than 2 prior line of chemotherapy

          -  For Part 3, prior treatment with no more than 1 prior line of chemotherapy

          -  For Parts 1 and 2, prior treatment with less than 4 prior endocrine therapies for
             metastatic breast cancer

          -  For Part 3, prior treatment with no more than 1 prior line of endocrine therapies for
             metastatic breast cancer

          -  For Parts 1 and 2, patients must satisfy 1 of the following criteria for prior
             therapy:

               -  Progressed during treatment or within 12 months of completion of adjuvant therapy
                  with an aromatase inhibitor

               -  Progressed after the end of prior aromatase inhibitor therapy for
                  advanced/metastatic breast cancer

          -  For Part 3, patients must satisfy 1 of the following criteria for prior therapy:

               -  Received ≥ 24 months of endocrine therapy in the adjuvant setting prior to
                  recurrence or progression

               -  Received ≥ 6 months of endocrine therapy in the advanced/metastatic setting prior
                  to progression

          -  For Part 1, evaluable or measurable disease

          -  For Parts 2 and 3, evaluable (approximately 25%) or measurable disease (approximately
             75%) as defined by RECIST, Version 1.1 including bone-only disease

          -  ECOG performance status 0 to 1

          -  Adequate organ function

        Exclusion Criteria:

          -  For Part 3, prior treatment with CDK4/6 inhibitor, investigational oral SERDs or
             SERCAs in any setting

          -  Active uncontrolled/symptomatic CNS metastases, carcinomatous meningitis, or
             leptomeningeal disease

          -  Anticancer therapy within 14 days of first G1T48 dose or within 28 days for
             antibody-based therapy

          -  Concurrent radiotherapy, radiotherapy within 14 days of first G1T48 dose, previous
             radiotherapy to the target lesion sites, or prior radiotherapy to &gt; 25% of bone marrow

          -  Prior hematopoietic stem cell or bone marrow transplantation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Contact</last_name>
    <role>Study Director</role>
    <affiliation>G1 Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>G1 Therapeutics Clinical Contact</last_name>
    <phone>919-213-9835</phone>
    <email>clinicalinfo@g1therapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beverly Hills Cancer Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Linnea Chap, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Women Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Pegram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gail Wright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University - Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Massimo Cristofanilli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claire Dees, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Susanna Ulahannan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erika Hamilton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Aftimos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrick Neven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ARENSIA Exploratory Medicine LLC</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marina Maglakelidze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ARENSIA Exploratory Medicine Phase I Unit, The Institute of Oncology</name>
      <address>
        <city>Chisinau</city>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Iurie Bulat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>C. Willimien Menke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elisabeth de Vries, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Agnes Jager, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Georgia</country>
    <country>Moldova, Republic of</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2018</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Oral SERD</keyword>
  <keyword>SERD</keyword>
  <keyword>HER2-Negative</keyword>
  <keyword>ER-Positive</keyword>
  <keyword>ER+</keyword>
  <keyword>HER2-</keyword>
  <keyword>HER2 -ve</keyword>
  <keyword>ER +ve</keyword>
  <keyword>CDK 4/6 Inhibitor</keyword>
  <keyword>Rintodestrant</keyword>
  <keyword>G1T48</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

